Previous 10 | Next 10 |
Agilent (NYSE: A ) initiated with Hold rating and $85 (11% upside) price target at Stifel. More news on: Agilent Technologies, Inc., Avantor, Inc., Bio-Techne Corporation, Healthcare stocks news, Stocks on the move, , Read more ...
Investment Thesis I like the look of Repligen (RGEN). The company operates in a growing market, supplying tools for the manufacture of biologic drugs, most notably monoclonal antibodies. It has a proven ability to make strategic acquisitions that complement its business model and capabilitie...
Repligen Corporation (RGEN) Q3 2019 Earnings Conference Call October 31, 2019 08:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Executive Officer Jon Snodgres - Chief Financial Officer Conference Call Participant...
Image source: The Motley Fool. Repligen (NASDAQ: RGEN) Q3 2019 Earnings Call Oct 31, 2019 , 8:30 a.m. ET Operator Continue reading
After an eventful first half of the year, Repligen (NASDAQ: RGEN) turned in a relatively ho-hum performance in the third quarter. To be fair, revenue grew 40% year over year and the company raised full-year 2019 revenue guidance, but investors have come to expect that from the bioprocessing ...
Repligen (NASDAQ: RGEN ): Q3 Non-GAAP EPS of $0.26; GAAP EPS of $0.03 misses by $0.03 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...
Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year Raises revenue guidance to $267-$270 million for full year 2019, representing 31%-32% organic growth WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Repligen Corpor...
WALTHAM, Mass., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2019 financial results on Thursday, October 31, 2019. The Company will issue a press release before the market opens and will host a conference...
It may not be as sexy as biopharmaceutical companies developing gene therapies or tailoring the next big cellular medicines, but Repligen (NASDAQ: RGEN) has certainly rewarded investors through its leadership position in bioprocess engineering. The stock has delivered a 10-year return of 1,4...
Shares of Repligen (NASDAQ: RGEN) fell more than 17% last month, according to data provided by S&P Global Market Intelligence . In fact, September was the stock's worst month of 2019, although there wasn't any company-specific news to justify the drop. This simply appears to be a case o...
News, Short Squeeze, Breakout and More Instantly...
WALTHAM, Mass., July 16, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2024 financial results on Tuesday, July 30, 2024. The Company will issue a press release before the market opens and will host a conference call at ...
2024-07-04 04:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-21 14:00:08 ET Daniel Arias from Stifel Nicolaus issued a price target of $207.00 for RGEN on 2024-06-21 12:12:00. The adjusted price target was set to $207.00. At the time of the announcement, RGEN was trading at $123.16. The overall price target consensus is at...